---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-07T02:55:40.601964'
end_time: '2026-09-07T03:07:58.176741'
duration_seconds: 737.58
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Developmental and Epileptic Encephalopathy 19
  mondo_id: MONDO:0014328
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 23
reference_validation:
  total_references: 23
  verified: 23
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 23
  on_topic: 19
  validator_version: 0.2.1
term_validation:
  total_terms: 50
  verified: 47
  not_found: 0
  obsolete: 1
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 30
  labels_matching: 20
  labels_mismatched: 4
  mislabelled_terms:
  - term_id: GO:0005783
    reported_labels:
    - mislocalization site
    - endoplasmic reticulum
    ontology_label: endoplasmic reticulum
  - term_id: NCIT:C935
    reported_labels:
    - valproate
    ontology_label: Vindesine Sulfate
  - term_id: NCIT:C62735
    reported_labels:
    - ketogenic diet
    - Non-pharmacologic:** **ketogenic diet
    ontology_label: Vaccine-Draining Lymph Node Lymphocyte Therapy
  - term_id: NCBITaxon:10116
    reported_labels:
    - Gabra1
    ontology_label: Rattus norvegicus
  labels_variant: 6
  obsolete_terms:
  - term_id: GO:0005887
    ontology_label: GO_0005887
    replaced_by: GO:0005886
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Developmental and Epileptic Encephalopathy 19
- **MONDO ID:** MONDO:0014328 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Developmental and Epileptic Encephalopathy 19** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Developmental and Epileptic Encephalopathy 19 (DEE19) — Comprehensive Disease Report

**Disease:** Developmental and Epileptic Encephalopathy 19 (DEE19)
**MONDO:** MONDO:0014328 | **OMIM:** 615744 | **Causal gene:** *GABRA1* (HGNC:4075)
**Report type:** Disease-level aggregation from primary literature and ontology/database knowledge (not individual EHR-derived).

> Evidence-source key: **[H]** human clinical, **[V]** in vitro/heterologous expression, **[M]** model organism, **[C]** computational. Frequencies for rare, ultra-rare disorders are qualitative unless a cohort number is given. Where a claim reflects general DEE/GABAA biology rather than a DEE19-specific study, this is stated explicitly.

---

## 1. Disease Information

**Overview.** DEE19 is a rare, genetically determined developmental and epileptic encephalopathy caused by heterozygous, usually *de novo*, pathogenic variants in *GABRA1*, the gene encoding the α1 subunit of the type A γ-aminobutyric acid (GABA-A) receptor. It presents in infancy with multiple, frequently drug-resistant seizure types accompanied by developmental delay/intellectual disability. The term "developmental **and** epileptic encephalopathy" denotes that impairment arises both from the underlying genetic lesion acting on brain development (the developmental encephalopathy) **and** from the epileptic activity itself worsening function (the epileptic encephalopathy).

**Key identifiers.**
- **OMIM:** 615744 (Developmental and epileptic encephalopathy 19; formerly "Epileptic encephalopathy, early infantile, 19 / EIEE19")
- **MONDO:** MONDO:0014328
- **Gene OMIM:** *GABRA1* 137160
- **Orphanet:** within "Non-syndromic genetic developmental and epileptic encephalopathy" (ORPHA:442835) and the GABRA1-related epilepsy spectrum; DEE has no single unique ORPHA number for the 19 subtype.
- **ICD-10:** G40.4 (Other generalized epilepsy and epileptic syndromes) / G40.83 (in some coding sets). **ICD-11:** 8A61 / 8A6Z (Developmental and epileptic encephalopathies).
- **MeSH:** "Spasms, Infantile" / "Epileptic Syndromes" / "Epilepsy, Generalized" (no unique DEE19 MeSH; indexed under GABRA1 and epileptic encephalopathy).
- **HGNC:** 4075; **NCBI Gene:** 2554; **Ensembl:** ENSG00000022355; **UniProt:** P14867 (GBRA1_HUMAN).

**Synonyms / alternative names.** Early infantile epileptic encephalopathy 19 (EIEE19); GABRA1-related epileptic encephalopathy; GABRA1-related developmental and epileptic encephalopathy; GABRA1 epilepsy. The *GABRA1* allelic spectrum also includes juvenile myoclonic epilepsy (JME, OMIM 611136) and childhood absence epilepsy susceptibility.

**Data provenance.** Content here is aggregated at the disease level from primary case series, functional studies, mechanistic reviews, and curated databases (OMIM, ClinVar, HPO, Orphanet); it is not derived from a single patient EHR.

---

## 2. Etiology

**Primary cause — genetic (monogenic, dominant).** DEE19 is caused by pathogenic variants in *GABRA1*. The first *GABRA1* epilepsy variant (p.Ala322Asp, A322D) was identified in a large French-Canadian JME family (Cossette et al. 2002 **[H/V]**, PMID:11992121): *"an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy."* Severe encephalopathic phenotypes arise chiefly from *de novo* variants (Hernandez et al. 2019 **[H/V]**, PMID:31056671): *"two known GABRA1 mutations (c.335G>A, p.R112Q and c.343A>G, p.N115D) in six patients with intractable early onset epileptic encephalopathy."*

**Genetic risk factors.** The causal variant itself is the risk factor. Most DEE19 variants are *de novo* dominant (see §9). No independent susceptibility loci or modifier genes are established for DEE19 specifically; general genetic-background modifiers are plausible but unproven.

**Environmental risk factors.** None established as causal. DEE19 is a monogenic disorder; environment does not initiate disease. General seizure-provoking factors (fever, sleep deprivation, missed medication, intercurrent illness) can precipitate seizures in an already-affected individual but are triggers, not causes.

**Protective factors.** No genetic protective alleles are defined. The only "protective" influence is functional: variants retaining greater residual GABA-A receptor function tend to produce milder phenotypes (Boßelmann et al. 2026 **[H/C]**, PMID:42546502; GABRA3 paralog paradigm, Johannesen et al. 2026 **[H/M]**, PMID:41289009). Effective early seizure control is the main modifiable protective factor against epileptic-encephalopathy worsening.

**Gene–environment interactions.** Not a major feature; disease is genetically determined. GxE is limited to environmental seizure triggers acting on the genetic substrate.

---

## 3. Phenotypes

DEE19 is clinically variable; the following are the characteristic features. HPO terms are suggested; frequencies are qualitative/cohort-based given rarity.

**Core neurological phenotypes**
- **Seizures**, multiple types — the defining feature (obligate, ~100%). Types include generalized tonic-clonic, myoclonic, focal, atonic, absence, tonic, and epileptic spasms. HP:0001250 (Seizure), HP:0002133 (Status epilepticus), HP:0002123 (Generalized myoclonic seizure), HP:0002069 (Generalized tonic-clonic seizure), HP:0011153 (Focal-onset seizure), HP:0011097 (Epileptic spasm), HP:0002121 (Absence seizure).
- **Global developmental delay / intellectual disability** (very frequent, ~most patients; severity mild→profound). HP:0001263 (Global developmental delay), HP:0001249 (Intellectual disability).
- **Developmental regression / stagnation with seizure onset** (encephalopathy). HP:0002376 (Developmental regression).
- **Hypotonia** (frequent). HP:0001252 (Hypotonia).
- **Ataxia / movement abnormalities / dystonia** (subset). HP:0001251 (Ataxia), HP:0001332 (Dystonia).
- **Abnormal EEG** — multifocal/generalized epileptiform discharges; hypsarrhythmia in those with spasms; sometimes photosensitivity. HP:0002353 (EEG abnormality), HP:0002521 (Hypsarrhythmia).
- **Speech/language impairment**, absent or limited speech. HP:0002463 (Language impairment), HP:0001344 (Absent speech).
- **Behavioral features** — autistic features, hyperactivity/ADHD-like behavior in a subset. HP:0000729 (Autistic behavior), HP:0000752 (Hyperactivity).
- **Microcephaly** (subset, acquired or congenital). HP:0000252 (Microcephaly).

**Onset:** infantile, typically first months of life; in an 8-patient GABRA1 cohort onset was **3–8 months** (Zhang & Liu 2022 **[H]**, PMID:35937053): *"Epilepsy onset age was between 3 and 8 months of age."* Milder allelic phenotypes (JME) present in adolescence.

**Severity/progression:** variable severity (mild epilepsy → severe DEE); seizure course is often chronic and drug-resistant with an epileptic-encephalopathy plateau; developmental trajectory is impaired and largely static-to-slowly-progressive rather than neurodegenerative.

**Quality-of-life impact:** severe. Refractory seizures, intellectual disability, communication and motor impairment produce high dependency, need for caregiving, and reduced QoL for patient and family. No DEE19-specific EQ-5D/SF-36 data exist; QoL burden is inferred from severe DEE literature.

---

## 4. Genetic / Molecular Information

**Causal gene.** *GABRA1* (HGNC:4075; NCBI Gene 2554; OMIM 137160; UniProt P14867), on chromosome **5q34**, encoding the GABA-A receptor α1 subunit (a Cys-loop ligand-gated ion channel subunit with a large extracellular N-terminal GABA-binding domain and four transmembrane helices M1–M4; M2 lines the chloride pore).

**Pathogenic variants.**
- **Variant type/class:** predominantly heterozygous **missense** variants; also nonsense/frameshift (haploinsufficiency) and splice variants. Reported pathogenic missense residues cluster in (i) the **N-terminal GABA-binding domain** (e.g., p.Arg112Gln/R112Q, p.Asn115Asp/N115D) and (ii) **transmembrane domains** (e.g., p.Pro260Ser/P260S, p.Leu296Ser/L296S, p.Trp315Leu/W315L, p.Ala322Asp/A322D) (Hernandez et al. 2019 **[H/V]**, PMID:31056671; Krampfl et al. 2005 **[V]**, PMID:16029191). *"The α1(R112Q and N115R) subunit residue substitutions were in the N-terminal GABA binding domain."*
- **Classification (ACMG/AMP):** most recurrent DEE19 variants are Pathogenic/Likely pathogenic in ClinVar; PS2 (*de novo*), PM2 (absent from gnomAD), PS3 (functional studies), PP2 (missense-intolerant gene) commonly apply. VUS exist and benefit from functional/computational LoF-vs-GoF classification (Boßelmann et al. 2026 **[H/C]**, PMID:42546502).
- **Allele frequency:** pathogenic DEE19 variants are absent/ultra-rare in population databases (gnomAD); *GABRA1* is highly constrained (high missense/LoF intolerance).
- **Somatic vs germline:** germline (constitutional). *De novo* germline events dominate severe cases; parental germline mosaicism is possible (see §9). No somatic-mosaicism disease role established.
- **Functional consequence:** predominantly **loss-of-function** (reduced surface expression, impaired biogenesis, reduced GABA sensitivity/gating), but a subset — particularly pore-lining M2 variants — are **gain-of-function** (Boßelmann 2026, PMID:42546502; paralog GABRA3, PMID:41289009). Dominant-negative effects on assembled receptors are described for some variants.

**Modifier genes.** None validated for DEE19. Genetic background likely contributes to variable expressivity.

**Epigenetic information.** No DEE19-specific DNA-methylation "episignature" is established. (Some other DEE genes have episignatures; *GABRA1* is not a recognized episignature disorder to date.)

**Chromosomal abnormalities.** DEE19 is typically a single-nucleotide/small-indel disorder. Larger 5q34 deletions encompassing *GABRA1* (contiguous *GABRA1/GABRB2/GABRG2* cluster) can occur and are detectable by chromosomal microarray, but classic DEE19 is not a copy-number syndrome.

---

## 5. Environmental Information

- **Environmental factors:** none causal. Not applicable as an etiology.
- **Lifestyle factors:** not applicable to disease causation. Standard seizure hygiene (sleep, adherence) modulates seizure frequency.
- **Infectious agents:** none. DEE19 is genetic, not infectious. (In differential diagnosis, acquired/infectious encephalopathies must be excluded — see §10.)

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. A heterozygous (usually *de novo*) **pathogenic variant in *GABRA1*** alters the α1 subunit protein sequence. *(demonstrated)*
2. This **leads to** abnormal α1 subunit biogenesis: impaired folding, endoplasmic-reticulum retention, and **excessive ER-associated degradation (ERAD)** of the misfolded subunit at the expense of forward trafficking, reducing oligomerization/trafficking and **cell-surface expression** of α1-containing GABA-A receptors (Krampfl 2005 **[V]**, PMID:16029191; Macdonald 2010 **[V]**, PMID:20308251; Hernandez 2016 **[V]**, PMID:27622563; for the archetype A322D, Fu 2018 **[V]**, PMID:30481215: *"the A322D mutation in the α1 subunit... causes its extensive misfolding and expedited degradation in the endoplasmic reticulum (ER)"*). *(demonstrated in vitro)* — This ERAD/proteostasis defect is pharmacologically reversible (see §12), implicating GO:0036503 (ERAD pathway) and GO:0030968 (ER unfolded protein response).
3. In parallel, surface-expressed mutant receptors show **reduced GABA-binding affinity and impaired channel gating** (reduced current amplitude, altered activation/deactivation) (Krampfl 2005; Cossette 2002). Branch: rare M2/pore variants instead **increase** channel activity → **gain-of-function** (Boßelmann 2026 **[H/C]**, PMID:42546502). *(demonstrated)*
4. Reduced/altered α1β2γ2 receptor function **results in** decreased fast phasic GABAergic inhibitory postsynaptic currents (reduced mIPSC amplitude/frequency) at inhibitory synapses (mouse VB thalamus, Zhou 2015 **[M]**, PMID:25447232). *(demonstrated in model; inferred in human)*
5. Loss of inhibition **leads to** a cortical/thalamocortical **excitation–inhibition imbalance and neuronal hyperexcitability**, with disinhibition of thalamic relay nuclei promoting abnormal thalamocortical oscillations (Zhou 2015 **[M]**). *(demonstrated in model)*
6. Hyperexcitability **results in** recurrent, multifocal/generalized **seizures** (clinical). *(demonstrated)*
7. Because α1-GABA-A signaling also shapes **early neurodevelopment** (during the developmental period GABA is depolarizing/excitatory and guides proliferation, migration, differentiation, synaptogenesis; Stojanovic 2016 **[H]**, PMID:26518133), receptor dysfunction during a **critical infantile window** — compounded by the deleterious effect of ongoing seizures on the developing network — **leads to** **developmental delay/intellectual disability and encephalopathy** (the "developmental" + "epileptic" encephalopathy). *(partly inferred)*
8. For gain-of-function variants, excess/altered GABAergic signaling similarly **results in** severe, treatment-resistant epilepsy and profound impairment, by analogy to the GABRA3 paralog paradigm (Johannesen 2026 **[H/M]**, PMID:41289009). *(inferred by paralogy)*

### Detail by category
- **Molecular pathways:** GABAergic inhibitory neurotransmission via the ionotropic GABA-A receptor–chloride channel; no canonical growth-factor signaling cascade. GO:0007214 (GABA receptor signaling pathway); GO:1902476 (chloride transmembrane transport); Reactome "GABA A receptor activation."
- **Cellular processes:** loss of fast synaptic inhibition; E/I imbalance; during development, altered neuronal proliferation/migration/synapse maturation (GO:0060078 regulation of postsynaptic membrane potential; GO:0007268 chemical synaptic transmission).
- **Protein dysfunction:** misfolding, ER retention, impaired assembly/trafficking → reduced surface receptor; and/or altered ligand binding and gating. Loss-of-function predominant; gain-of-function and dominant-negative subsets.
- **Metabolic changes:** none primary. (Ketogenic diet may help empirically via network effects, not a defined metabolic defect.)
- **Immune involvement:** none; not autoimmune/inflammatory.
- **Tissue-damage mechanisms:** not degenerative; injury is functional (network dysfunction) plus potential secondary excitotoxic effects of prolonged seizures/status epilepticus.
- **Biochemical abnormality:** ligand-gated **ion channel (chloride) dysfunction** — a channelopathy of inhibitory neurotransmission.
- **Epigenetic changes:** none established.
- **Molecular profiling:** no disease-specific transcriptomic/proteomic/metabolomic signature; mechanistic data derive from heterologous electrophysiology, cryo-EM structure (α1β3γ2; Laverty 2019 **[V]**, PMID:30602789), and mouse models.

**Cell types (CL):** GABAergic inhibitory interneuron (CL:0000617), neuron (CL:0000540), pyramidal/glutamatergic neuron (postsynaptic target; CL:0000598), thalamic relay neuron. **Subcellular (GO CC):** postsynaptic membrane GO:0045211; GABA-A receptor complex GO:1902711; integral component of plasma membrane GO:0005887; endoplasmic reticulum GO:0005783 (mislocalization site). **CHEBI:** GABA (CHEBI:16865), chloride (CHEBI:17996).

---

## 7. Anatomical Structures Affected

- **Organ / system:** the **brain** and central nervous system (nervous system, UBERON:0001016). Primary organ: brain (UBERON:0000955); cerebral cortex (UBERON:0000956), thalamus (UBERON:0001897, thalamocortical circuits implicated by mouse data), hippocampus (UBERON:0002421), cerebellum (α1 highly expressed; UBERON:0002037). No primary involvement of non-neural organs; systemic effects are secondary to disability (e.g., feeding/respiratory complications).
- **Tissue/cell level:** nervous tissue; GABAergic inhibitory synapses on cortical and thalamic neurons. Affected cell populations: inhibitory interneurons and their postsynaptic partners (CL:0000617 GABAergic neuron; CL:0000540 neuron).
- **Subcellular level:** the **inhibitory postsynaptic membrane** (GO:0045211) and the **GABA-A receptor–chloride channel complex** (GO:1902711); with variant protein mislocalized to the **endoplasmic reticulum** (GO:0005783).
- **Localization / lateralization:** **bilateral, diffuse** cortical involvement (generalized encephalopathy); EEG discharges may be generalized or multifocal. Not a focal/lateralized lesional disorder, though asymmetric epileptiform features can occur.

---

## 8. Temporal Development

- **Onset:** congenital genetic lesion with clinical onset typically in **infancy (first year, commonly 3–8 months)** for DEE19; milder allelic phenotypes (JME) present in adolescence. Onset pattern: subacute/insidious emergence of seizures with developmental slowing.
- **Progression:** chronic, lifelong. Seizures are frequently drug-resistant; course is often an early "stormy" phase followed by a plateau (epileptic-encephalopathy pattern). Not classically neurodegenerative; developmental impairment is largely static-to-slowly-evolving.
- **Course pattern:** chronic with episodic seizure clusters and possible status epilepticus; some patients improve in seizure control over time while cognitive impairment persists.
- **Remission:** true remission is uncommon in severe DEE19; seizure freedom is treatment-dependent and variable. Milder allelic phenotypes can be well-controlled.
- **Critical period:** the **infantile window** of synaptic maturation is both the period of maximal vulnerability and the key window for early, effective seizure control and developmental intervention (rationale from developmental GABA biology, PMID:26518133).

---

## 9. Inheritance and Population

- **Epidemiology:** DEE19 is an **ultra-rare** disorder; no precise prevalence/incidence figures are established (individual GABAA-DEE subtypes each account for a small fraction of DEEs). DEEs collectively affect on the order of ~1 in 2,000 children. *GABRA1* is a recognized but minority cause among genetic DEEs.
- **Inheritance:** **autosomal dominant**, most often **de novo** in severe DEE19; **inherited autosomal-dominant** transmission occurs for milder alleles (e.g., the A322D JME family, Cossette 2002, PMID:11992121).
- **Penetrance:** high for severe *de novo* variants; **incomplete/variable penetrance and expressivity** for some inherited alleles (same variant can yield JME in one relative and more severe epilepsy in another).
- **Expressivity:** **highly variable** — a hallmark of *GABRA1* (mild IGE ↔ severe DEE), partly explained by variant functional class (LoF vs GoF; PMID:42546502).
- **Genetic anticipation:** not applicable (not a repeat-expansion disorder).
- **Germline mosaicism:** possible; recurrence in siblings of unaffected parents has been reported for DEE genes generally, warranting counseling.
- **Founder effects:** the A322D JME variant is notable in a French-Canadian pedigree but is family-specific, not a population founder allele.
- **Consanguinity:** not relevant (dominant mechanism).
- **Carrier frequency:** not applicable (dominant, typically *de novo*; pathogenic alleles absent from population databases).
- **Population demographics:** no ethnic predilection; reported worldwide. **Sex ratio ~1:1** (autosomal; the 8-patient cohort was 4 male/4 female, PMID:35937053). Age distribution skews to pediatric onset.

---

## 10. Diagnostics

- **Genetic testing (definitive):** **exome or genome sequencing**, or a **multigene epilepsy/DEE panel** including *GABRA1*, is the diagnostic mainstay; **trio** testing establishes *de novo* status. Single-gene *GABRA1* testing is appropriate when the phenotype is highly suggestive. WES/WGS diagnostic yield in early-onset DEE is high (e.g., ~40–72% for onset <3 months; Thanuja & Kamate 2025 **[H]**, PMID:40088508: *"WES gave an overall yield of 61.9%... and 71.4%... in cases with epilepsy onset before three months."*). Early genetic diagnosis frequently changes management (Elkhateeb 2024 **[H]**, PMID:38221827; Esterhuizen 2023 **[H]**, PMID:36480001).
- **Chromosomal microarray (CMA):** to detect 5q34 deletions involving the *GABRA* cluster; usually normal in point-variant DEE19.
- **Karyotype/FISH/mtDNA/repeat-expansion testing:** generally not informative; used to exclude alternative etiologies.
- **Variant interpretation:** ACMG/AMP criteria; functional and computational LoF-vs-GoF classification refines VUS and guides therapy (PMID:42546502).
- **Electrophysiology:** **EEG** is central — multifocal/generalized epileptiform discharges; hypsarrhythmia if spasms; used for seizure classification and monitoring.
- **Neuroimaging:** **brain MRI** is typically normal or shows nonspecific findings (e.g., mild atrophy/delayed myelination); primarily excludes structural/malformative causes.
- **Laboratory/biomarkers:** no specific blood/CSF biomarker; metabolic workup (including CSF neurotransmitters, lactate) is used to exclude treatable metabolic epilepsies. The genetic variant is the definitive molecular marker.
- **Clinical criteria:** diagnosis follows the **ILAE** framework for developmental and epileptic encephalopathy (early-onset refractory seizures + developmental impairment) plus a confirmed pathogenic *GABRA1* variant.
- **Differential diagnosis:** other genetic DEEs — *SCN1A* (Dravet), *KCNQ2*, *STXBP1*, *CDKL5*, *SCN2A*, *SCN8A*, *KCNT1*, other GABAA genes (*GABRB3*, *GABRG2*, *GABRB2*, *GABRA5*); structural/metabolic/hypoxic-ischemic encephalopathies; pyridoxine-dependent epilepsy. Distinguished by gene testing and electroclinical pattern.
- **Screening:** not part of newborn screening; **cascade testing** of relatives and prenatal/preimplantation testing available once the familial variant is known.

---

## 11. Outcome / Prognosis

- **Survival/mortality:** no DEE19-specific survival figures. Severe DEEs carry elevated mortality including **SUDEP** and status epilepticus (Klein 2025 **[H]**, PMID:40105713: *"...refractory to treatment and to have high mortality rates."*). Life expectancy is reduced in severely affected, non-ambulant, refractory patients; milder cases have near-normal survival.
- **Morbidity/function:** high — intellectual disability, motor impairment, communication deficits, dependency; frequent comorbid autism/ADHD-like behavior. Long-term disability is the norm in severe cases.
- **Disease course/complications:** drug-resistant epilepsy is common; DEEs show the **highest drug-resistance rate among childhood epilepsy syndromes (77.7%)** (Ayoub et al. 2024 **[H]**, PMID:39150742). Complications: status epilepticus, injury from seizures, aspiration, feeding difficulty, SUDEP.
- **Recovery potential:** limited for cognitive deficits; seizure control may improve with tailored therapy but developmental impairment usually persists.
- **Prognostic factors:** earlier onset, multiple seizure types, myoclonus, and greater developmental delay predict drug resistance/poorer outcome (PMID:39150742). **Variant functional class** (GoF associated with more severe, treatment-resistant disease) is an emerging molecular prognostic marker (PMID:42546502, PMID:41289009).

---

## 12. Treatment

**General principle:** symptomatic seizure control plus developmental support; increasingly **genotype-guided** based on LoF vs GoF variant classification.

- **Pharmacotherapy (antiseizure medications, NCIT: Antiepileptic Agent):** broad-spectrum ASMs are used empirically — **valproate** (NCIT:C935), **levetiracetam**, **clobazam** and other **benzodiazepines** (NCIT:C29075; GABA-A positive modulators), **topiramate**, **lamotrigine**, **zonisamide**, and for spasms **vigabatrin**/ACTH/corticosteroids. **Cenobamate** is a newer ASM with efficacy in refractory epilepsy/DEE (Klein 2025 **[H]**, PMID:40105713). Because most DEE19 variants are LoF, drugs that **enhance residual GABA-A function** (benzodiazepines) are mechanistically rational; conversely, GABA-enhancing drugs may be counterproductive for GoF variants — underscoring functional classification.
- **Precision/personalized medicine:** **vinpocetine** is an emerging targeted therapy for **loss-of-function** GABAA/*GABRA1* DEE — adjunctive vinpocetine reduced seizure frequency and improved comorbidities in a case series of 9 patients with 8 GABAA-receptor variants (Gjerulfsen et al. 2026 **[H/V]**, PMID:42227896): *"Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA[A receptor variants]."* LoF-vs-GoF prediction models directly inform drug selection (Boßelmann 2026 **[H/C]**, PMID:42546502).
- **Non-pharmacologic:** **ketogenic diet** (NCIT:C62735) is used empirically for refractory DEE; **vagus nerve stimulation**; epilepsy surgery is generally not applicable (non-lesional, generalized).
- **Advanced / experimental targeted therapeutics:** For loss-of-function variants that impair receptor **biogenesis/trafficking** (e.g., A322D), **proteostasis-modulating** strategies rescue mutant surface expression and chloride current in cell models — the BiP/HSP70 activator **BIX** and modest activation of the **ATF6/IRE1 unfolded-protein-response** pathways (Fu 2018 **[V]**, PMID:30481215), and **VCP/p97 inhibition (Eeyarestatin I) plus the folding enhancer SAHA/vorinostat** (Han 2015 **[V]**, PMID:25406314). Ongoing work maps the GABAA proteostasis network to find drug-correctable variants (PMID:36030824, PMID:40112516, PMID:40161784, PMID:41178115). These are **preclinical/experimental**, not yet clinical. No approved gene therapy, ASO, or cell therapy for DEE19; conceptually attractive for a dominant channelopathy and under preclinical consideration.
- **Supportive/rehabilitative:** physical, occupational, and speech therapy; developmental/educational support; nutritional and respiratory care; management of behavioral comorbidities.
- **Treatment outcomes/adverse events:** response is variable and often partial; polytherapy is common; standard ASM adverse-event profiles apply (sedation, hepatotoxicity/valproate, behavioral effects/levetiracetam, visual-field effects/vigabatrin).
- **Strategy:** individualized, guided by seizure type, EEG, and increasingly variant functional class; combination therapy is frequent in refractory disease.

---

## 13. Prevention

- **Primary prevention:** not possible for *de novo* genetic disease. **Genetic counseling** for families with a known variant; **prenatal diagnosis / preimplantation genetic testing (PGT)** can prevent recurrence when a familial pathogenic variant is identified.
- **Secondary prevention:** early genetic diagnosis enables **early, targeted seizure control** to mitigate epileptic-encephalopathy worsening (rationale: developmental critical period, PMID:26518133; value of early diagnosis, PMID:38221827).
- **Tertiary prevention:** optimize seizure control to reduce status epilepticus and SUDEP risk; early developmental therapies; treat comorbidities.
- **Immunization / infectious control:** not applicable (non-infectious); routine vaccination is encouraged as intercurrent illness/fever can trigger seizures.
- **Counseling:** recurrence risk generally low for *de novo* cases but with a caveat for **germline mosaicism**; 50% transmission risk for an affected parent carrying a dominant allele.

---

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** *GABRA1* is highly conserved across vertebrates. Mouse *Gabra1* (NCBI Gene 14394; **Mus musculus**, NCBITaxon:10090); rat *Gabra1* (NCBITaxon:10116); zebrafish *gabra1* (**Danio rerio**, NCBITaxon:7955). Strong evolutionary conservation of the GABA-A receptor and its inhibitory function underlies cross-species modeling.
- **Natural disease in other species:** no well-characterized naturally occurring *GABRA1* epileptic-encephalopathy analog documented in companion animals (OMIA has no established *GABRA1* DEE entry); GABAergic mechanisms are broadly implicated in animal seizure disorders. Veterinary relevance is chiefly as experimental models rather than spontaneous disease.
- **Comparative biology:** the conserved role of α1-GABA-A receptors in fast inhibition means mechanistic findings translate across mammals; evolutionary conservation supports use of mouse/zebrafish models.
- **Transmission:** not applicable (non-communicable genetic disease; no zoonotic potential).

---

## 15. Model Organisms

- **Mouse (Mus musculus, NCBITaxon:10090) — primary model.** **Heterozygous *Gabra1* deletion** produces **absence seizures** and reduced thalamic inhibition (Zhou et al. 2015 **[M]**, PMID:25447232): *"heterozygous deletion of Gabra1, the mouse homolog of the human absence epilepsy gene that encodes the GABAA receptor (GABAAR) α1 subunit, causes absence seizures."* Demonstrates reduced synaptic α1, reduced mIPSC amplitude/frequency, ventrobasal-thalamus disinhibition, and partial cortical compensation (α3 upregulation). Knock-in of specific human variants and paralog GoF knock-ins (e.g., *Gabra3*^Q242L/+ showing increased seizure susceptibility, early death, cortical hyperexcitability; PMID:41289009 **[M]**) model genotype-specific mechanisms.
- **Model types available:** knockout, heterozygous null, and knock-in (point-variant "humanized") mice; conditional alleles feasible via MGI/IMPC resources.
- **In vitro / cellular models:** heterologous expression (HEK293, *Xenopus* oocytes) of recombinant α1β2/β3γ2 receptors for electrophysiology and trafficking assays (Cossette 2002; Krampfl 2005; Hernandez 2016) — the workhorse for LoF/GoF functional classification; patient-derived iPSC neurons are an emerging platform.
- **Phenotype recapitulation:** mouse *Gabra1* models reproduce **seizures and reduced inhibition** well; they capture the core channelopathy and network disinhibition.
- **Limitations:** heterozygous-null mice model absence-type seizures better than the full severe human DEE19 encephalopathy; compensatory subunit upregulation and species differences in subunit expression limit full phenotype capture; cognitive/developmental phenotypes are only partially modeled.
- **Resources:** MGI (mouse), ZFIN (zebrafish), RGD (rat), IMPC/IMSR for strains; Alliance of Genome Resources for orthology.

---

## Summary of Findings, Supported and Refuted Hypotheses

**Answer to the research question.** DEE19 (OMIM 615744; MONDO:0014328) is a rare autosomal-dominant, usually *de novo*, developmental and epileptic encephalopathy caused by pathogenic variants in *GABRA1* (GABA-A receptor α1 subunit). Variants impair fast GABAergic inhibition — predominantly by loss of function (defective receptor biogenesis, surface expression, GABA sensitivity, and gating), with a gain-of-function subset — producing cortical/thalamocortical excitation–inhibition imbalance that manifests as infantile-onset, often drug-resistant multi-type seizures with developmental delay/intellectual disability.

**Supported hypotheses:** (1) *GABRA1* is the causal gene [strong: human genetics + functional data]; (2) loss-of-function/impaired inhibition is the dominant mechanism [strong: in vitro + mouse]; (3) variant functional class (LoF vs GoF) drives severity and treatment direction [emerging, strong]; (4) genotype-guided therapy (e.g., vinpocetine for LoF) is rational and clinically promising [emerging].

**Refuted / not-applicable:** environmental, infectious, autoimmune, metabolic, and epigenetic-episignature etiologies are **not** primary causes; DEE19 is a monogenic channelopathy.

**Limitations & future directions.** Precise epidemiology, natural-history/QoL metrics, and controlled treatment-outcome data specific to DEE19 are lacking; the pubmed corpus queried here was limited, so some claims lean on GABAA-DEE-wide and paralog evidence. Priorities: variant-specific functional maps (LoF vs GoF), prospective genotype-stratified trials (vinpocetine and GABA-A enhancers for LoF; caution/antagonism strategies for GoF), **clinical translation of proteostasis-corrector approaches** for biogenesis-defective variants (BiP/UPR modulators, VCP inhibition + HDAC inhibitors), iPSC/knock-in disease modeling, and development of allele-selective gene-based therapies (ASO/gene replacement) for this dominant channelopathy.

---

### Key references (PMID)
- 11992121 — Cossette 2002, first *GABRA1* (A322D) epilepsy variant.
- 16029191 — Krampfl 2005, A322D severe loss-of-function mechanisms.
- 20308251 — Macdonald 2010, GABAA subunit epilepsy mechanisms review.
- 27622563 — Hernandez 2016, GABR variant functional risk.
- 31056671 — Hernandez 2019, *de novo GABRA1* in early-onset epileptic encephalopathy.
- 35937053 — Zhang & Liu 2022, GABRA1 pediatric cohort (onset 3–8 mo).
- 25447232 — Zhou 2015, *Gabra1* mouse absence-seizure model.
- 26518133 — Stojanovic 2016, developmental α1 expression / excitatory GABA.
- 30602789 — Laverty 2019, cryo-EM α1β3γ2 structure.
- 42546502 — Boßelmann 2026, LoF/GoF prediction (505 individuals).
- 42227896 — Gjerulfsen 2026, vinpocetine precision therapy for LoF GABAA DEE.
- 41289009 — Johannesen 2026, GABRA3 paralog LoF/GoF paradigm.
- 30481215 — Fu 2018, ERAD/proteostasis rescue (BIX, ATF6/IRE1) of misfolded α1(A322D).
- 25406314 — Han 2015, VCP inhibition + SAHA restores trafficking-deficient α1(A322D).
- 36030824 / 40112516 / 40161784 / 41178115 — GABAA proteostasis network and correctors (experimental).
- 39150742 — Ayoub 2024, drug-resistance in DEE (77.7%).
- 40105713 — Klein 2025, refractory DEE, high mortality, cenobamate.
- 40088508 / 38221827 / 36480001 — WES yield & value of early genetic diagnosis in DEE.


## Artifacts

- [OpenScientist final report](Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Developmental_And_Epileptic_Encephalopathy_19-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 23 |
| Resolved | 23 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 23 |
| On topic | 19 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 50 |
| Resolved | 47 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 1 |
| Unverifiable | 2 |
| Terms whose name was checked | 30 |
| Terms named correctly | 20 |
| Terms named as a **different** term | 4 |
| Terms whose name is worth a second look | 6 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `GO:0005783` (2 mentions) - the report calls it "mislocalization site", "endoplasmic reticulum"; GO calls it **endoplasmic reticulum**
- `NCIT:C935` (1 mention) - the report calls it "valproate"; NCIT calls it **Vindesine Sulfate**
- `NCIT:C62735` (1 mention) - the report calls it "ketogenic diet", "Non-pharmacologic:** **ketogenic diet"; NCIT calls it **Vaccine-Draining Lymph Node Lymphocyte Therapy**
- `NCBITaxon:10116` (1 mention) - the report calls it "Gabra1"; NCBITaxon calls it **Rattus norvegicus**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0005887` (GO_0005887) (1 mention) - replaced by `GO:0005886`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002069` (1 mention) - the report calls it "Generalized tonic-clonic seizure"; HP calls it **Bilateral tonic-clonic seizure**
- `HP:0011153` (1 mention) - the report calls it "Focal-onset seizure"; HP calls it **Focal motor seizure**
- `GO:0030968` (1 mention) - the report calls it "ER unfolded protein response"; GO calls it **endoplasmic reticulum unfolded protein response**, and lists "ER unfolded protein response" among its other names
- `GO:0007214` (1 mention) - the report calls it "GABA receptor signaling pathway"; GO calls it **gamma-aminobutyric acid signaling pathway**, and lists "GABA signaling pathway" among its other names
- `GO:0045211` (2 mentions) - the report calls it "inhibitory postsynaptic membrane", "Subcellular level:** the **inhibitory postsynaptic membrane"; GO calls it **postsynaptic membrane**
- `GO:1902711` (2 mentions) - the report calls it "GABA-A receptor–chloride channel complex"; GO calls it **GABA-A receptor complex**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `ORPHA:442835` - called "Non-syndromic genetic developmental and epileptic encephalopathy", "Orphanet:** within "Non-syndromic genetic developmental and epileptic encephalopathy"
- `GO:0045211` - called "inhibitory postsynaptic membrane", "Subcellular level:** the **inhibitory postsynaptic membrane"
- `GO:0005783` - called "mislocalization site", "endoplasmic reticulum"
- `NCIT:C62735` - called "ketogenic diet", "Non-pharmacologic:** **ketogenic diet"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.